Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 1
2002 8
2003 9
2004 6
2005 7
2006 12
2007 4
2008 11
2009 17
2010 12
2011 19
2012 17
2013 7
2014 13
2015 7
2016 9
2017 16
2018 9
2019 10
2020 13
2021 10
2022 8
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Multiple angiosarcomas of both breasts: a case report.
Matsuda R, Saimura M, Anan K, Katsuyama K, Tahara Y, Kurata K, Horioka K, Nakamoto M, Koga K, Mitsuyama S, Sato E, Wakamatsu S, Tamiya S. Matsuda R, et al. Among authors: sato e. Surg Case Rep. 2023 Nov 28;9(1):205. doi: 10.1186/s40792-023-01782-w. Surg Case Rep. 2023. PMID: 38015377 Free PMC article.
Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma.
Ura A, Hayashi T, Komura K, Hosoya M, Takamochi K, Sato E, Saito S, Wakai S, Handa T, Saito T, Kato S, Suzuki K, Yao T; Tokyo Metropolitan Innovative Oncology Research Group (TMIG). Ura A, et al. Among authors: sato e. J Pathol Clin Res. 2024 Jan;10(1):e350. doi: 10.1002/cjp2.350. Epub 2023 Nov 16. J Pathol Clin Res. 2024. PMID: 37974379 Free PMC article.
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M, Kato K, Endo M, Matsumoto Y, Kakunaga S, Sato E, Miyahara Y, Morino K, Tanaka S, Takahashi S, Matsuo F, Matsumine A, Kageyama S, Ueda T. Kawai A, et al. Among authors: sato e. Clin Cancer Res. 2023 Dec 15;29(24):5069-5078. doi: 10.1158/1078-0432.CCR-23-1456. Clin Cancer Res. 2023. PMID: 37792433 Free PMC article. Clinical Trial.
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Fujikawa K, Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Fujikawa K, et al. Among authors: sato e. PLoS One. 2023 Sep 20;18(9):e0291772. doi: 10.1371/journal.pone.0291772. eCollection 2023. PLoS One. 2023. PMID: 37729184 Free PMC article. Clinical Trial.
Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.
Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K; REACH-J CKD collaborators. Kurasawa S, et al. Hypertens Res. 2023 Nov;46(11):2478-2487. doi: 10.1038/s41440-023-01358-z. Epub 2023 Jul 18. Hypertens Res. 2023. PMID: 37460823
Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
Hayashi Y, Makino T, Sato E, Ohshima K, Nogi Y, Kanemura T, Honma K, Yamashita K, Saito T, Tanaka K, Yamamoto K, Takahashi T, Kurokawa Y, Miyata H, Nakajima K, Wada H, Morii E, Eguchi H, Doki Y. Hayashi Y, et al. Among authors: sato e. Br J Cancer. 2023 Jun;128(12):2175-2185. doi: 10.1038/s41416-023-02235-9. Epub 2023 Apr 4. Br J Cancer. 2023. PMID: 37016103 Free PMC article.
Development of multiple AI pipelines that predict neoadjuvant chemotherapy response of breast cancer using H&E-stained tissues.
Shen B, Saito A, Ueda A, Fujita K, Nagamatsu Y, Hashimoto M, Kobayashi M, Mirza AH, Graf HP, Cosatto E, Hazama S, Nagano H, Sato E, Matsubayashi J, Nagao T, Cheng E, Hoda SA, Ishikawa T, Kuroda M. Shen B, et al. Among authors: sato e. J Pathol Clin Res. 2023 May;9(3):182-194. doi: 10.1002/cjp2.314. Epub 2023 Mar 10. J Pathol Clin Res. 2023. PMID: 36896856 Free PMC article.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: sato e. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Identification and functional analysis of three novel genetic variants resulting in premature termination codons in three unrelated patients with hereditary antithrombin deficiency.
Imai Y, Nagaya S, Araiso Y, Meguro-Horike M, Togashi T, Ohmori K, Makita Y, Sato E, Yujiri T, Nagamori Y, Horike SI, Watanabe A, Morishita E. Imai Y, et al. Among authors: sato e. Int J Hematol. 2023 Apr;117(4):523-529. doi: 10.1007/s12185-022-03509-3. Epub 2022 Dec 16. Int J Hematol. 2023. PMID: 36526880
211 results